Modulation and detection of tau aggregation with small-molecule ligands

Current Alzheimer Research

Volumn 6, Issue 5, 2009, Pages 409-414

  Chang, Edward ^a   Honson, Nicolette S ^a   Bandyopadhyay, Bhaswati ^a   Funk, Kristen E ^a   Jensen, Jordan R ^a   Kim, Sohee ^a   Naphade, Swati ^a   Kuret, Jeff ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Aggregation; Alzheimer's disease; Frontotemporal lobar degeneration; Neurofibrillary tangle; Paired helical filaments; Tau

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANILINE DERIVATIVE; BENZENE DERIVATIVE; CARBOCYANINE; CONGO RED; CYANINE DYE; DIRECT YELLOW 7; PHENYLTHIAZOLYLHYDRIDE DERIVATIVE; RHODANINE; TAU PROTEIN; THIACARBOCYANINE DERIVATIVE; THIAZINE DERIVATIVE; THIAZINE RED; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BINDING AFFINITY; BINDING SITE; CONFERENCE PAPER; DEGENERATIVE DISEASE; HUMAN; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; STOICHIOMETRY;

ALZHEIMER DISEASE; BRAIN; HUMANS; METHYLENE BLUE; NEUROFIBRILLARY TANGLES; TAU PROTEINS;

EID: 70249102095     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720509789207976     Document Type: Conference Paper

References (68)

1. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 82: 239-259 (1991).
2. von Bergen M, Barghorn S, Muller SA, Pickhardt M, Biernat J, Mandelkow EM, et al. The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry 45: 6446-6457 (2006). (Pubitemid 43787810)
3. Ksiezak-Reding H, Wall JS. Characterization of paired helical filaments by scanning transmission electron microscopy. Microsc Res Tech 67: 126-140 (2005). (Pubitemid 41243631)
4. Krebs MR, Bromley EH, Donald AM. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol 149: 30-37 (2005).
5. Gazit E. A possible role for pi-stacking in the self-assembly of amyloid fibrils. FASEB J 16: 77-83 (2002). (Pubitemid 34027953)
6. Wu C, Wang Z, Lei H, Duan Y, Bowers MT, Shea JE. The binding of thioflavin T and its neutral analog BTA-1 to protofibrils of the Alzheimer's Disease Abeta(16-22) peptide probed by molecular dynamics simulations. J Mol Biol 384: 718-729 (2008).
7. Wu C, Wang Z, Lei H, Zhang W, Duan Y. Dual binding modes of Congo red to amyloid protofibril surface observed in molecular dynamics simulations. J Am Chem Soc 129: 1225-1232 (2007). (Pubitemid 46208593)
8. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J. Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 363: 229-234 (2007).
9. Vallet PG, Guntern R, Hof PR, Golaz J, Delacourte A, Robakis NK, et al. A comparative study of histological and immunohistochemical methods for neurofibrillary tangles and senile plaques in Alzheimer's disease. Acta Neuropathol 83: 170-178 (1992).
10. Lockhart A, Ye L, Judd DB, Merritt AT, Lowe PN, Morgenstern JL, et al. Evidence for the presence of three distinct binding sites for the thioflavin T class of Alzheimer's disease PET imaging agents on beta-amyloid peptide fibrils. J Biol Chem 280: 7677-7684 (2005). (Pubitemid 40349660)
11. Ye L, Morgenstern JL, Gee AD, Hong G, Brown J, Lockhart A. Delineation of positron emission tomography imaging agent binding sites on β-amyloid peptide fibrils. J Biol Chem 280: 23599-23604 (2005). (Pubitemid 40884839)
12. Small GW, Bookheimer SY, Thompson PM, Cole GM, Huang SC, Kepe V, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol 7: 161-172 (2008).
13. Golde TE. Disease modifying therapy for AD? J Neurochem 99:689-707 (2006).
14. Ghoshal N, Garcia-Sierra F, Wuu J, Leurgans S, Bennett DA, Berry RW, et al. Tau conformational changes correspond to impairments of episodic memory in mild cognitive impairment and Alzheimer's disease. Exp Neurol 177: 475-493 (2002). (Pubitemid 35366136)
15. Royall DR, Palmer R, Mulroy AR, Polk MJ, Roman GC, David JP, et al. Pathological determinants of the transition to clinical dementia in Alzheimer's disease. Exp Aging Res 28: 143-162 (2002). (Pubitemid 34269909)
16. Shin J, Lee SY, Kim SH, Kim YB, Cho ZH. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 43: 236-244 (2008).
17. Agdeppa ED, Kepe V, Liu J, Flores-Torres S, Satyamurthy N, Petric A, et al. Binding characteristics of radiofluorinated 6-dialkylamino-2- naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease. J Neurosci 21: RC189 (2001).
18. Okamura N, Suemoto T, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H, et al. A novel imaging probe for in vivo detection of neuritic and diffuse amyloid plaques in the brain. J Mol Neurosci 24: 247-255 (2004).
19. Styren SD, Hamilton RL, Styren GC, Klunk WE. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 48: 1223-1232 (2000).
20. Ikonomovic MD, Abrahamson EE, Isanski BA, Debnath ML, Mathis CA, Dekosky ST, et al. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol 412: 123-144 (2006).
21. Klunk WE, Lopresti BJ, Ikonomovic MD, Lefterov IM, Koldamova RP, Abrahamson EE, et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25: 10598-10606 (2005).
22. Okamura N, Suemoto T, Furumoto S, Suzuki M, Shimadzu H, Akatsu H, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 25: 10857-10862 (2005).
23. Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule- associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem 59: 750-753 (1992).
24. Li R, Lindholm K, Yang LB, Yue X, Citron M, Yan R, et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci USA 101: 3632-3637 (2004). (Pubitemid 38338246)
25. Wang J, Dickson DW, Trojanowski JQ, Lee VM. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158: 328-337 (1999). (Pubitemid 29382824)
26. Ye L, Velasco A, Fraser G, Beach TG, Sue L, Osredkar T, et al. In vitro high affinity α-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 105: 1428-1437 (2008).
27. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46: 2740-2754 (2003).
28. Lockhart A. Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discov Today 11: 1093-1099 (2006). (Pubitemid 44803111)
29. Ye L, Morgenstern JL, Lamb JR, Lockhart A. Characterisation of the binding of amyloid imaging tracers to rodent Aβ fibrils and rodent-human Aβ co-polymers. Biochem Biophys Res Commun 347: 669-677 (2006). (Pubitemid 44109675)
30. Novak M, Kabat J, Wischik CM. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. EMBO J 12: 365-370 (1993). (Pubitemid 23042416)
31. Rademakers R, Cruts M, van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies. Hum Mutat 24: 277-295 (2004). (Pubitemid 39336634)
32. Chirita CN, Congdon EE, Yin H, Kuret J. Triggers of full-length tau aggregation: a role for partially folded intermediates. Biochemistry 44: 5862-5872 (2005). (Pubitemid 40525123)
33. Gotz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K, et al. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. EMBO J 14: 1304-1313 (1995).
34. Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, et al. Characterization of pathology in transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol Dis 7: 87-98 (2000). (Pubitemid 30241205)
35. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, Hutton M, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293: 711-714 (2001). (Pubitemid 32728676)
36. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M, et al. Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27: 3650-3662 (2007). (Pubitemid 46557687)
37. DeTure M, Ko LW, Yen S, Nacharaju P, Easson C, Lewis J, et al. Missense tau mutations identified in FTDP-17 have a small effect on tau-microtubule interactions. Brain Res 853: 5-14 (2000). (Pubitemid 30015993)
38. Gotz J, Chen F, Barmettler R, Nitsch RM. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 276: 529-534 (2001). (Pubitemid 32050347)
39. Lim F, Hernandez F, Lucas JJ, Gomez-Ramos P, Moran MA, Avila J. FTDP-17 mutations in tau transgenic mice provoke lysosomal abnormalities and Tau filaments in forebrain. Mol Cell Neurosci 18: 702-714 (2001). (Pubitemid 34060150)
40. Tanemura K, Akagi T, Murayama M, Kikuchi N, Murayama O, Hashikawa T, et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol Dis 8: 1036-1045 (2001). (Pubitemid 34017097)
41. Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T, et al. Aberrant tau phosphorylation by glycogen synthase kinase-3β and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem 277: 42060-42065 (2002). (Pubitemid 35257520)
42. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481 (2005). (Pubitemid 40994688)
43. Rosenmann H, Grigoriadis N, Eldar-Levy H, Avital A, Rozenstein L, Touloumi O, et al. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics. Exp Neurol 212: 71-84 (2008).
44. Sahara N, Murayama M, Lee B, Park JM, Lagalwar S, Binder LI, et al. Active c-jun N-terminal kinase induces caspase cleavage of tau and additional phosphorylation by GSK-3β is required for tau aggregation. Eur J Neurosci 27: 2897-2906 (2008). (Pubitemid 351832217)
45. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383: 550-553 (1996). (Pubitemid 26346185)
46. Perez M, Valpuesta JM, Medina M, Montejo de Garcini E, Avila J. Polymerization of tau into filaments in the presence of heparin: the minimal sequence required for tau-tau interaction. J Neurochem 67: 1183-1190 (1996). (Pubitemid 26277931)
47. Chirita CN, Necula M, Kuret J. Anionic Micelles and Vesicles Induce tau Fibrillization in vitro. J Biol Chem 278: 25644-25650 (2003).
48. Shirahama K, Tsujii K, Takagi T. Free-boundary electrophoresis of sodium dodecyl sulfate-protein polypeptide complexes with special reference to SDS-polyacrylamide gel electrophoresis. J Biochem 75: 309-319 (1974).
49. Congdon EE, Kim S, Bonchak J, Songrug T, Matzavinos A, Kuret J. Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants. J Biol Chem 283: 13806-13816 (2008).
50. Kim YS, Randolph TW, Manning MC, Stevens FJ, Carpenter JF. Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem 278: 10842-10850 (2003).
51. Chang E, Kim S, Yin H, Nagaraja HN, Kuret J. Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps. J Neurochem 107: 1113-1123 (2008).
52. Bandyopadhyay B, Li G, Yin H, Kuret J. Tau aggregation and toxicity in a cell culture model of tauopathy. J Biol Chem 282: 16454-16464 (2007). (Pubitemid 47100356)
53. Gross PG, Kartalov EP, Scherer A, Weiner LP. Applications of microfluidics for neuronal studies. J Neurol Sci 252: 135-143 (2007).
54. Mocanu MM, Nissen A, Eckermann K, Khlistunova I, Biernat J, Drexler D, et al. The potential for β-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci 28: 737-748 (2008). (Pubitemid 351159036)
55. (tm) arrests disease progression in mild and moderate Alzheimer's disease over 50 weeks. 11th International Conference on Alzheimer's Disease. Chicago, IL, 2008.
56. Wendel WB. The Control of Methemoglobinemia with Methylene Blue. J Clin Invest 18: 179-185 (1939).
57. Atamna H, Nguyen A, Schultz C, Boyle K, Newberry J, Kato H, et al. Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 22: 703-712 (2008). (Pubitemid 351348123)
58. Larbig G, Pickhardt M, Lloyd DG, Schmidt B, Mandelkow E. Screening for inhibitors of tau protein aggregation into Alzheimer paired helical filaments: a ligand based approach results in successful scaffold hopping. Curr Alzheimer Res 4: 315-323 (2007). (Pubitemid 47025430)
59. Mandelkow E, Mandelkow E-M, Biernat J, Bergen MV, Pickhardt M. Treating neurodegenerative conditions. PCT International Application WO 007864 A1 (2006).
60. Taniguchi S, Suzuki N, Masuda M, Hisanaga S, Iwatsubo T, Goedert M, et al. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. J Biol Chem 280: 7614-7623 (2005). (Pubitemid 40349654)
61. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of β-synuclein and disaggregates existing fibrils. J Biol Chem 279: 26846-26857 (2004). (Pubitemid 38812518)
62. Crowe A, Ballatore C, Hyde E, Trojanowski JQ, Lee VM. High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation. Biochem Biophys Res Commun 358: 1-6 (2007). (Pubitemid 46719073)
63. Pickhardt M, Larbig G, Khlistunova I, Coksezen A, Meyer B, Mandelkow EM, et al. Phenylthiazolyl-hydrazide and its derivatives are potent inhibitors of tau aggregation and toxicity in vitro and in cells. Biochemistry 46: 10016-10023 (2007).
64. Pickhardt M, Biernat J, Khlistunova I, Wang YP, Gazova Z, Mandelkow EM, et al. N-phenylamine derivatives as aggregation inhibitors in cell models of tauopathy. Curr Alzheimer Res 4: 397-402 (2007). (Pubitemid 47416632)
65. Bulic B, Pickhardt M, Khlistunova I, Biernat J, Mandelkow EM, Mandelkow E, et al. Rhodanine-based tau aggregation inhibitors in cell models of tauopathy. Angew Chem Int Ed Engl 46: 9215-9219 (2007). (Pubitemid 350292144)
66. Chirita C, Necula M, Kuret J. Ligand-dependent inhibition and reversal of tau filament formation. Biochemistry 43: 2879-2887 (2004). (Pubitemid 38327819)
67. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, et al. Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 46: 8850-8860 (2007). (Pubitemid 47208418)
68. Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 282: 10311-10324 (2007). (Pubitemid 47093410)